Antibacterial activity of ceftizoxime (FK 749), a new cephalosporin, against cephalosporin-resistant bacteria, and its stability to beta-lactamase.

AUTOR(ES)

Kojo, H

RESUMO

Antibacterial activity of FK 749 against ampicillin-resistant clinical isolates of Escherichia coli was compared with those of other newly developed cephalosporins. FK 749 was the most active against strains possessing R-plasmids specifying ampicillin resistance and those whose resistance was chromosomally determined. The susceptibility of ampicillin-susceptible E. coli to FK 749 was not decreased by transduction of ampicillin resistance-specifying plasmids. However, most of the transconjugants acquired a high level of resistance to cefoperazone and cefamandole and a moderate level of resistance to cefoperazone and cefamandole and a moderate level to cefotiam. FK 749 was highly stable to both penicillinase- and cephalosporinase-type beta-lactamases, including R-plasmid-mediated beta-lactamase. Its level of resistance to beta-lactamases was comparable to those of cefoxitin, cefmetazole, and cefotaxime, slightly superior to that of cefuroxime, and much superior to those of cefotiam, cefamandole, and cefoperazone.

Documentos Relacionados

• Ceftizoxime (FK 749), a new parenteral cephalosporin: in vitro and in vivo antibacterial activities.
• Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.
• In vitro antibacterial activity and beta-lactamase stability of E-0702, a new cephalosporin.
• In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin.
• Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin.